Is Biodesix Inc (BDSX) overvalued? · rev $71.3M
Biodesix Inc (BDSX) is a diagnostics & research company listed on NASDAQ.
This page asks whether Biodesix Inc (BDSX) looks expensive on cached numbers — not a short thesis.
Latest reported BDSX revenue for 2024-12-31 was $71.3M. Net income was -$42.9M. Revenue was up 45.3% from 2023-12-31 to 2024-12-31. BDSX currently screens at market cap $157.6M.
BDSX currently screens at market cap $157.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BDSX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BDSX stock page for the full model, not this heading.
Not investment advice.